Equity
Additional Paid-In Capital
Royalty Pharma Additional Paid-In Capital increased by 6.3% to $4.38B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.1%, from $4.21B to $4.38B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows an upward trend with a 7.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ4 2015
Last reportedQ1 2026
How to read this metric
An increase typically signals equity financing or the issuance of shares for employee compensation.
Detailed definition
This represents the amount of capital received from shareholders in excess of the par value of the common stock. It is g...
Peer comparison
High levels are common in growth-oriented tech companies that utilize stock-based compensation to attract talent.
Metric ID:
additional_paid_in_capitalHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.42B | $3.45B | $3.51B | $3.54B | $3.57B | $3.63B | $3.67B | $3.74B | $4.03B | $4.01B | $4.01B | $4.07B | $4.10B | $4.11B | $4.10B | $4.21B | $4.13B | $4.11B | $4.12B | $4.38B |
| QoQ Change | — | +1.1% | +1.5% | +1.0% | +0.8% | +1.7% | +0.9% | +2.0% | +7.8% | -0.6% | +0.1% | +1.6% | +0.6% | +0.2% | -0.1% | +2.6% | -2.0% | -0.4% | +0.3% | +6.3% |
| YoY Change | — | — | — | — | +4.5% | +5.2% | +4.5% | +5.5% | +12.9% | +10.3% | +9.4% | +9.0% | +1.7% | +2.5% | +2.3% | +3.3% | +0.7% | +0.1% | +0.5% | +4.1% |
Range$3.42B – $4.38B
CAGR+5.4%
Avg YoY Growth+4.8%
Median YoY Growth+4.3%
Current Streak2 quarters growth
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's additional paid-in capital?
- Royalty Pharma (RPRX) reported additional paid-in capital of $4.38B in Q1 2026.
- How has Royalty Pharma's additional paid-in capital changed year-over-year?
- Royalty Pharma's additional paid-in capital increased by 4.1% year-over-year, from $4.21B to $4.38B.
- What is the long-term trend for Royalty Pharma's additional paid-in capital?
- Over 5 years (2020 to 2025), Royalty Pharma's additional paid-in capital has grown at a 7.5% compound annual growth rate (CAGR), from $2.87B to $4.12B.
- What does additional paid-in capital mean?
- Capital received from investors above the par value of the shares.